2.5K
RA🧬 Speaking in London this week at AI in Drug Discovery and I want to break down why this actually matters for all of us.
Developing a new drug used to take 10–15 years and cost over $1 billion. A lot of that time is spent reading research — millions of scientific papers, clinical trial results, lab findings. No human team can read it all.
That’s where AI comes in. 🤖
Imagine you’re trying to find a cure for Alzheimer’s. AI can scan decades of published research in minutes, connect dots between a protein studied in 2003 and a gene mutation discovered last year, and suggest which drug compounds are worth testing before a single experiment is run.
But here’s the catch and it’s what my talk is about:
AI can only retrieve what it actually has access to. If the knowledge sources feeding it are incomplete, locked behind paywalls, or low quality… the AI doesn’t just fail silently. It makes things up.
That’s not a minor bug when we’re talking about medicine.
My session: “What your AI can’t retrieve, it will invent” because the quality of information behind AI systems isn’t just a technical problem. It’s a patient safety problem.
Grateful to be bringing Wiley’s perspective to this conversation alongside speakers from GSK, Roche, Novartis, Eli Lilly, and more.
If you’re here in London, come say hello. 🇬🇧
#AIDrugDiscovery #AIInMedicine #PharmaInnovation #Biotech GenerativeAI
@raulproduct
